Evidence map›Paper›PMID 38856835›Full record

ReviewMolecular diversity2025

Anticancer potential and structure activity studies of purine and pyrimidine derivatives: an updated review.

Tanushree Manna, Sumit Maji, Mousumi Maity, Biplab Debnath, Shambo Panda, Shah Alam Khan, Rajarshi Nath, Md Jawaid Akhtar

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tanushree MannaDepartment of Pharmacy, Bharat Technology, Uluberia, 711316, Howrah, West Bengal, India.
Sumit MajiDepartment of Pharmacy, Bharat Technology, Uluberia, 711316, Howrah, West Bengal, India.
Mousumi MaityDepartment of Pharmacy, Bharat Technology, Uluberia, 711316, Howrah, West Bengal, India.
Biplab DebnathDepartment of Pharmacy, Bharat Technology, Uluberia, 711316, Howrah, West Bengal, India.
Shambo PandaDepartment of Pharmacy, Bharat Technology, Uluberia, 711316, Howrah, West Bengal, India.
Shah Alam KhanDepartment of Pharmaceutical Chemistry, National University of Science and Technology, PC 130, Azaiba, Bousher, PO 620, Muscat, Sultanate of Oman.
Rajarshi NathDepartment of Pharmacy, Bharat Technology, Uluberia, 711316, Howrah, West Bengal, India. rajarshinath69@gmail.com.
Md Jawaid AkhtarDepartment of Pharmaceutical Chemistry, National University of Science and Technology, PC 130, Azaiba, Bousher, PO 620, Muscat, Sultanate of Oman. mjawaid@nu.edu.om.

Funding

National University of Science and Technology, Muscat, Sultanate of Oman NUFRG/22/CP/0011
6 · The paper itself

Abstract

Cancer is the world's leading cause of death impacting millions of lives globally. The increasing research over the past several decades has focused on the development of new anticancer drugs, but still cancer continues to be a global health challenge. Thus, several new alternative therapeutic strategies have been tried for the drug design and discovery. Purine and pyrimidine heterocyclic compounds have received attention recently due to their potential in targeting various cancers. It is evident from the recently published data over the last decade that incorporation of the purine and pyrimidine rings in the synthesized derivatives resulted in the development of potent anticancer molecules. This review presents synthetic strategies encompassing several examples of recently developed purine and pyrimidine-containing compounds as anticancer agents. In addition, their structure-activity relationships are represented in the schemes indicating the fragment or groups that are essential for the enhanced anticancer activities. Purine and pyrimidines combined with other heterocyclic compounds have resulted in many novel anticancer molecules that address the challenges of drug resistance. The purine and pyrimidine derivatives showed significantly enhanced anticancer activities against targeted receptor proteins with numerous compounds with an IC

Indexed as

Antineoplastic AgentsNeoplasmsPurinesPyrimidinesAnimalsHumansStructure-Activity RelationshipAntineoplastic AgentsPurinespyrimidinePyrimidinesCancerHeterocyclic compoundsNucleobasesPurinePyrimidine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.